Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24253402 | 0.86 | HSP90AA1 (0.41) | IDO1TDO2HSP90AA1HSP90AB1LMNA | |
| SCHEMBL16744223 | 0.84 | IDO1 (0.42) | IDO1TDO2HSP90AA1HSP90AB1 | |
| SCHEMBL24874256 | 0.77 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL24924704 | 0.73 | IDO1 (0.36) | IDO1TDO2 | |
| SCHEMBL24924432 | 0.72 | TBXAS1 (0.36) | IDO1TDO2HSP90AA1HSP90AB1LMNA | |
| SCHEMBL24248985 | 0.70 | LMNA (0.40) | HSP90AA1HSP90AB1LMNATRPA1CHRM1 | |
| SCHEMBL25064769 | 0.69 | IDO1 (0.34) | IDO1TDO2 | |
| SCHEMBL20315035 | 0.69 | HSP90AA1 (0.35) | IDO1TDO2HSP90AA1HSP90AB1 | |
| SCHEMBL16589292 | 0.66 | TBXAS1 (0.39) | IDO1TDO2LMNA | |
| SCHEMBL16471465 | 0.66 | PRKCI (0.31) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048890-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | IDO1 4834/4885TDO2 4874/4885HSP90AA1 2009/4885 |
| US-20230008867-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | IDO1 4821/4885TDO2 4862/4885HSP90AA1 2130/4885 |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | IDO1 4821/4885TDO2 4862/4885HSP90AA1 2130/4885 |
| US-20230009712-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | IDO1 4834/4885TDO2 4874/4885HSP90AA1 2009/4885 |
| US-20230069804-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | IDO1 4834/4885TDO2 4874/4885HSP90AA1 2009/4885 |
| US-20230054781-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | IDO1 4834/4885TDO2 4874/4885HSP90AA1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.